Joint Corp (NASDAQ:JYNT) shot up 8.5% during trading on Friday . The stock traded as high as $2.31 and last traded at $2.31, with a volume of 62,607 shares. The stock had previously closed at $2.13.

JYNT has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Joint Corp from a “sell” rating to a “hold” rating in a report on Tuesday, May 17th. Feltl & Co. cut shares of Joint Corp from a “strong-buy” rating to a “buy” rating in a report on Friday, June 24th. Finally, Maxim Group decreased their target price on shares of Joint Corp from $8.00 to $5.00 and set a “buy” rating for the company in a report on Friday, July 1st.

The stock’s market capitalization is $30.52 million. The stock has a 50-day moving average of $2.25 and a 200 day moving average of $3.03.

Joint Corp (NASDAQ:JYNT) last announced its quarterly earnings results on Thursday, August 11th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm had revenue of $5 million for the quarter, compared to analyst estimates of $3.40 million. Equities analysts predict that Joint Corp will post ($0.97) EPS for the current fiscal year.

In related news, major shareholder Glenhill Advisors Llc acquired 80,069 shares of Joint Corp stock in a transaction that occurred on Friday, July 1st. The shares were purchased at an average cost of $1.97 per share, for a total transaction of $157,735.93. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.